From: When do patient reported quality of life indicators become prognostic in breast cancer?
Overall | Trial VI | Trial VII | Trial VIII | Trial IX | Trial 13 | Trial 14 | Trial 15 | |
---|---|---|---|---|---|---|---|---|
Patients enrolled | 8024 | 1475 | 1212 | 1109 | 1669 | 1246 | 969 | 344 |
Patients who relapsed (analytic cohort) | 3247 | 848 | 656 | 281 | 339 | 511 | 417 | 195 |
Characteristics in analytic cohort | ||||||||
Age, median | 50 | 44 | 60 | 44 | 61 | 43 | 58 | 46 |
Range | 23–79 | 24–57 | 38–79 | 29–56 | 34–76 | 23–57 | 40–70 | 25–65 |
Menopausal, n (%) | 1475 (45.4) | 0 (0) | 656 (100) | 2 (0.7) | 339 (100) | 4 (0.8) | 413 (99.0) | 61 (31.3) |
Tumor >2 cm, n (%) | 1998 (62.8) | 523 (63.2) | 4 s24 (65.3) | 120 (43.2) | 182 (53.9) | 338 (68.2) | 270 (67.3) | 141 (72.7) |
1–3 involved axillary lymph nodes, n (%) | 1189 (36.6) | 454 (53.5) | 338 (51.5) | 0 (0) | 1 (0.3) | 250 (48.9) | 146 (35.0) | 0 (0) |
≥ 4 involved axillary lymph nodes, n (%) | 1438 (44.3) | 394 (46.5) | 318 (48.5) | 0 (0) | 0 (0) | 261 (51.1) | 270 (64.8) | 195 (100) |
Estrogen receptor positive, n (%) | 2154 (66.5) | 585 (69.0) | 485 (73.9) | 211 (75.4) | 256 (76.7) | 297 (58.1) | 245 (58.8) | 75 (38.7) |
Mastectomy, n (%) | 2258 (69.5) | 637 (75.1) | 543 (82.8) | 130 (46.3) | 182 (53.7) | 327 (64.0) | 291 (69.8) | 148 (75.9) |
Radiotherapy, n (%) | 979 (30.2) | 201 (23.7) | 106 (16.2) | 121 (43.1) | 128 (37.8) | 184 (36.0) | 128 (30.7) | 111 (56.9) |
QL data availability at 1, 2 or 3 months before relapsea, n (%) | 677 (20.9) | 187 (22.1) | 130 (19.8) | 59 (21.0) | 50 (14.7) | 106 (20.7) | 91 (21.8) | 54 (27.7) |
1 month | 199 | 39 | 34 | 17 | 15 | 36 | 31 | 27 |
2 months | 163 | 40 | 30 | 16 | 10 | 30 | 27 | 10 |
3 months | 315 | 108 | 66 | 26 | 25 | 40 | 33 | 17 |
QL data availability at or after relapseb, n (%) | 1309 (40.3) | 354 (41.7) | 262 (39.9) | 96 (34.2) | 102 (30.1) | 233 (45.6) | 170 (40.8) | 92 (47.2) |
First post-relapse reading | 1309 | 354 | 262 | 96 | 102 | 233 | 170 | 92 |
Second post-relapse reading | 661 | 188 | 135 | 57 | 45 | 125 | 70 | 41 |
Third post-relapse reading | 202 | 25 | 25 | 29 | 22 | 57 | 31 | 13 |